-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on RxSight, Raises Price Target to $9

Benzinga·02/26/2026 18:53:22
Listen to the news
UBS analyst Danielle Antalffy maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $8 to $9.